Emergingby GlyphLoyal's large-dog lifespan drug LOY-003 earns FDA RXE
LOY-003 became Loyal's third program to earn Reasonable Expectation of Effectiveness from the FDA.
loyal.com
Events in frontier tech
26 events
Sep 2026
Rentosertib trial data read out on six proteomic aging clocks
Nature Biotechnology reported that six clocks indicated reduced predicted biological age in treated IPF patients.
doi.org
Aug 2026
XPRIZE Healthspan advances 20 finalist teams
Ten of the finalists received $1 million milestone awards in the $101 million competition.
xprize.org
Jun 2026
First patient dosed with partial reprogramming therapy ER-100
Life Biosciences dosed the first participant in its Phase 1 trial of the OSK-based therapy.
lifebiosciences.com
May 2026
Calico and Nexo Therapeutics sign small molecule discovery deal
The companies will jointly pursue Calico-nominated targets for age-related diseases.
calicolabs.com
Feb 2026
ARPA-H funds seven teams under PROSPR
The awards back aging biomarkers and the first trials aimed at extending healthspan.
arpa-h.gov
Jan 2026
FDA clears IND for Life Biosciences' reprogramming therapy ER-100
The clearance lets a Phase 1 trial test ER-100 in glaucoma and NAION patients.
lifebiosciences.com
FDA accepts safety section for Loyal's LOY-002
The FDA's veterinary center accepted the target animal safety section of LOY-002's conditional approval file.
loyal.com
Dec 2025
BioAge reports interim Phase 1 data for NLRP3 inhibitor BGE-102
BGE-102 was well tolerated in dose cohorts and supported once-daily oral dosing.
sec.gov
Nov 2025
AbbVie ends its decade-long partnership with Calico
AbbVie ended the aging research alliance and laid off chemists working on it.
statnews.com
Sep 2025
Unity Biotechnology stockholders approve dissolution
A special meeting approved the plan to dissolve the senolytics company.
sec.gov
Aug 2025
Altos Labs reports mesenchymal drift reversed by partial reprogramming
A Cell paper found mesenchymal gene drift across aging tissues and showed partial reprogramming reverses it.
doi.org
Jul 2025
Loyal completes enrollment of the STAY study at 1,300 dogs
The LOY-002 trial enrolled 1,300 dogs across more than 70 clinics.
loyal.com
Jun 2025
Calico licenses Mabwell's IL-11 antibody for age-related disease
Calico gained exclusive rights to IL-11 directed therapeutics including the Phase 1 antibody 9MW3811.
calicolabs.com
Shift Bioscience reports single-gene target for safer cell rejuvenation
SB000 reversed cellular aging across cell types without triggering pluripotency pathways.
shiftbioscience.com
Nature Medicine publishes Phase 2a trial of AI-discovered drug rentosertib
A randomized trial of the generative AI-discovered TNIK inhibitor in lung fibrosis was published.
doi.org
May 2025
XPRIZE Healthspan names first milestone winners
The $101 million, seven-year prize announced its first milestone awards and top semifinalist teams.
xprize.org
Unity Biotechnology cuts all staff after ASPIRE data
Unity approved a reduction in force affecting all employees and began exploring strategic alternatives.
sec.gov
Apr 2025
Senolytic UBX1325 results for diabetic macular edema published
NEJM Evidence published safety and efficacy data for Unity's senolytic UBX1325 in diabetic macular edema.
doi.org
Loyal's STAY study enrolls 1,000 dogs
The LOY-002 trial hit its enrollment goal and expanded to up to 1,300 dogs.
loyal.com
Feb 2025
FDA accepts efficacy case for Loyal's senior dog lifespan drug
LOY-002 earned Reasonable Expectation of Effectiveness from the FDA, Loyal's second RXE.
loyal.com
Jan 2025
Calico's fosigotifator misses its goal in the HEALEY ALS platform trial
The eIF2B activator, developed with AbbVie, did not meet the primary endpoint in ALS.
calicolabs.com
Dec 2024
ARPA-H launches the PROSPR healthspan program
The US health research agency opened funding for therapies and biomarkers to extend healthspan.
arpa-h.gov
Nov 2024
Insilico reports positive Phase 2a results for its AI-designed IPF drug
ISM001-055 was safe and showed dose-dependent gains in lung function at 12 weeks.
insilico.com
Sep 2024
BioAge Labs prices its Nasdaq IPO
BioAge sold 11 million shares at $18.00 each and listed under the ticker BIOA.
sec.gov
Feb 2024
Loyal doses the first dog in its LOY-002 pivotal lifespan study
A senior dog named Boo became the first dog dosed in the STAY study of LOY-002.
loyal.com